Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2014 (2014), Article ID 793928, 3 pages
http://dx.doi.org/10.1155/2014/793928
Case Report

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine

National Hospital Organization, Osaka Minami Medical Center, 2-1 Kidohigashi, Kawachinagano, Osaka 586-8521, Japan

Received 7 February 2014; Accepted 16 March 2014; Published 31 March 2014

Academic Editor: Thomas R. Chauncey

Copyright © 2014 Takahiro Kumode et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. D. Cheson, J. M. Bennett, K. J. Kopecky et al., “Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia,” Journal of Clinical Oncology, vol. 21, no. 24, pp. 4642–4649, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Fenaux, G. J. Mufti, E. Hellström-Lindberg et al., “Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia,” Journal of Clinical Oncology, vol. 28, no. 4, pp. 562–569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. L. R. Silverman, D. R. McKenzie, B. L. Peterson et al., “Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 3895–3903, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Maurillo, A. Venditti, A. Spagnoli et al., “Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian compassionate program,” Cancer, vol. 118, no. 4, pp. 1014–1022, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. H. K. Al-Ali, N. Jaekel, C. Junghanss et al., “Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study,” Leukemia and Lymphoma, vol. 53, no. 1, pp. 110–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. L. H. van der Helm, E. R. Scheepers, N. J. Veeger et al., “Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients,” Journal of Hematology and Oncology, vol. 6, article 29, 2013. View at Google Scholar
  7. R. Itzykson, O. Kosmider, T. Cluzeau et al., “Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias,” Leukemia, vol. 25, no. 7, pp. 1147–1152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. T. Voso, E. Fabiani, A. Piciocchi et al., “Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine,” Leukemia, vol. 25, no. 12, pp. 1910–1913, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Kuendgen, C. Muller-Thomas, P. Urbaniak et al., “Possible biomarkers to predict response in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) treated with 5-azacitidine,” Blood, vol. 122, no. 21, abstract 2757, 2013. View at Google Scholar
  10. A. Kulasekararaj, A. Mohamedali, A. Smith et al., “Comprehensive mutational screening of 5-azacitidine treated myelodysplastic syndrome (MDS) patients fails to identify a specific mutational profile predicting response to therapy,” Blood, vol. 122, no. 21, abstract 2792, 2013. View at Google Scholar
  11. C. Muller-Thomas, M. Rudelius, I. Rondak et al., “Response to azacitidine is independent of TP53 mutations in higher-risk myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML),” Blood, vol. 122, no. 21, abstract 2797, 2013. View at Google Scholar
  12. J. S. Ahn, H. R. Kim, H. J. Kim et al., “Clinical significance of SF3B1, U2AF1 and SRSF2 spliceosomal gene mutations for the treatment of hypomethylating agents in myelodysplastic syndrome,” Blood, vol. 122, no. 21, abstract 2802, 2013. View at Google Scholar